Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4 by Todaro, M. et al.
Cell Stem Cell
ArticleColon Cancer Stem Cells Dictate
Tumor Growth and Resist Cell Death
by Production of Interleukin-4
Matilde Todaro,1 Mileidys Perez Alea,1 Anna B. Di Stefano,1 Patrizia Cammareri,3 Louis Vermeulen,5
Flora Iovino,1 Claudio Tripodo,4 Antonio Russo,2 Gaspare Gulotta,3 Jan Paul Medema,5,* and Giorgio Stassi1,*
1Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory
2Department of Surgical and Oncological Sciences, Oncological Unit
3Department of GENURTO
4Human Pathology Department
University of Palermo, 90127 Palermo, Italy
5Laboratory for Experimental Oncology and Radiobiology, Academic Medical Center, 1105AZ, Amsterdam,
the Netherlands
*Correspondence: gstassi@tiscali.it (G.S.), j.p.medema@amc.uva.nl (J.P.M.)
DOI 10.1016/j.stem.2007.08.001SUMMARY
A novel paradigm in tumor biology suggests
that cancer growth is driven by stem-like cells
within a tumor. Here, we describe the identifica-
tion and characterization of such cells from co-
lon carcinomas using the stem cell marker
CD133 that accounts around 2% of the cells in
human colon cancer. The CD133+ cells grow
in vitro as undifferentiated tumor spheroids,
and they are both necessary and sufficient to
initiate tumor growth in immunodeficient mice.
Xenografts resemble the original human tumor
maintaining the rare subpopulation of tumori-
genic CD133+ cells. Further analysis revealed
that the CD133+ cells produce and utilize
IL-4 to protect themselves from apoptosis.
Consistently, treatment with IL-4Ra antagonist
or anti-IL-4 neutralizing antibody strongly en-
hances the antitumor efficacy of standard
chemotherapeutic drugs through selective sen-
sitization of CD133+ cells. Our data suggest that
colon tumor growth is dictated by stem-like
cells that are treatment resistant due to the
autocrine production of IL-4.
INTRODUCTION
Colorectal cancer is the third most common visceral ma-
lignancy and remains one of the leading causes of can-
cer-related deaths due to therapy resistance (Greenlee
et al., 2001). Normal homeostasis in the intestinal tract is
regulated by a careful balance between cell proliferation,
differentiation, and apoptosis. Although this balance is
clearly disturbed in colorectal cancer, closer examination
of tumors from the colon reveals that there is heterogene-
ity within such tumors that may in part be due to (aberrant)Cedifferentiation of cancer cells. Until a few years ago, all
neoplastic cells within a tumor were suggested to contain
tumorigenic growth capacity, but recent evidence hints to
the possibility that this is confined to a small subset of can-
cer-initiating cells, so-called cancer stem cells (CSC) (Pre-
snell et al., 2002; Reya et al., 2001). The first evidence for
the existence of CSC was obtained in the context of acute
myeloid leukemia, where only a small portion of harvested
leukemic cells from patients could recapitulate the same
cancer in immune-deficient mice (Bonnet and Dick,
1997). Later on, CSC were also demonstrated to exist in
breast (Dontu et al., 2004) and brain tumors (Singh et al.,
2004). These cells express markers of stemness and are
also capable to reproduce the human cancer in mouse
models. Other reports extend this principle to prostate
(Collins et al., 2005), ovarian carcinoma (Bapat et al.,
2005), and melanoma (Fang et al., 2005). More recently,
two reports showed the existence of CSC in colon carci-
noma using CD133 as a marker (O’Brien et al., 2007;
Ricci-Vitiani et al., 2007). CD133 is infrequently expressed
in normal colon tissues as compared with the tumor tis-
sues (O’Brien et al., 2007). These reports suggest that co-
lon cancer is organized in a hierarchical fashion in which
the CD133+ tumor cells act as stem-like cells and thereby
give rise to more differentiated tumor cells. However, the
nature of these undifferentiated colon cancer cells and
the sensitivity of these cells for treatment requires further
investigation.
CSC are hypothesized to be inert to toxic environmental
agents due to high expression levels of ABC transporters,
active DNA-repair capacity, and resistance to apoptosis
(Dean et al., 2005). Alterations in the apoptotic machinery
have been related to chemoresistance in several tumor
types (Johnstone et al., 2002). We recently described
the resistance of cancer cells to apoptosis due to elevated
expression of antiapoptotic proteins, associated to the
autocrine production of IL-4 (Stassi et al., 2003; Todaro
et al., 2006). IL-4 has previously been reported to induce
apoptosis resistance in chronic lymphocytic leukemia B
cell and to enhance antiapoptotic protein expression inll Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc. 389
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Role of IL-4 on Colon Cancer Stem Cellsnormal and transformed lymphocytes (Dancescu et al.,
1992), as well as in prostate, breast, and bladder tumor
cell lines (Conticello et al., 2004). Additionally, it has
been demonstrated that IL-4 enhances proliferation of hu-
man pancreatic cancer cells, whereas blockage of this cy-
tokine on these tumor cells has a significant growth-inhib-
itory effect (Prokopchuk et al., 2005). Thus, it is likely that
IL-4 may promote cancer cell survival through upregula-
tion of antiapoptotic genes. Given this evidence, we de-
fined the tumorigenic stem-like cell population present in
colorectal carcinoma and analyzed whether this popula-
tion is more resistant to current therapies. Moreover, we
analyzed whether CSC can be sensitized to undergo
growth inhibition and cell death by neutralizing the IL-4
pathway.
RESULTS
Colon Cancer Contains Stem-like Cells
Several colon cancer specimens were characterized by
alcian blue and hematoxylin and eosin stainings; by immu-
nohistochemistry for CK20, CK7, the Ki67 antigen and the
homeodomain transcription factor CDX2 (Figure 1A); and
were typed for microsatellite instability (MSI) (Table 1).
Moreover, these tumors were analyzed for the expression
of CD133, a putative stem cell marker. Five (24%) tumors
from our cohort were MSI-high (MSI-H), six (28%) tumors
were MSI-low (MSI-L), and nine (48%) lacked MSI (MSS)
(Table 1). The CD133 cell antigen, which is expressed on
hematopoietic stem cells (Yin et al., 1997) and recently
used to identify brain (Singh et al., 2004), kidney (Bussolati
et al., 2005), colon (O’Brien et al., 2007; Ricci-Vitiani et al.,
2007), and prostate cancer stem-like cells (Collins et al.,
2005), was detected within the tumor specimens as well
(Figure 1A,B). A further analysis achieved on freshly puri-
fied cells from these tumors revealed that the percentage
of CD133+ cells in all patients ranges between 0.3%–3%
(Table 1 and Figure 1C left panel).
CD133+ Cells Mediate Tumor Growth
in Xenotransplants
To determine whether such CD133+ cells have tumori-
genic capacity and thus, in analogy with previous findings,
are required for successful xenotransplantation, we di-
gested primary tumor samples and analyzed their ability
to grow subcutaneously in immunodeficient mice. Freshly
dissociated cells from human cancer specimens (bulk) in-
jected at 0.5 or 2 3 106 cells per mouse were capable of
establishing subcutaneous tumors (Figure 1D). However,
depletion of the CD133+ cells (%0.08%; Figure 1C) from
the same tumor samples using magnetic bead cell sorting
drastically reduced tumor formation (Figure 1D). The fail-
ure of the CD133 population to form tumors after xeno-
transplantation was not due to a complete depletion of
cancer cells during the cell sorting procedure, as more
than 60% of the remaining CD133 cells were mutant
for P53 in four screened tumors (see Figure S1A in the
Supplemental Data available with this article online) and
both p53 and k-ras mutations were detected in the390 Cell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier InCD133 cells (Table S1). These observations confirm
that CD133 tumor cells do not induce tumor formation,
while as little as 2.5 3 103 or 5 3 103 of the purified
CD133+ cells, either derived from MSI or MSS tumors,
readily form tumors (Figure 1D).
The xenografts tumors that resulted from injection of
CD133+ cells presented the same histopathology features
as their respective human tumor and were composed of
CD133+/CD133 ratios similar to that observed in the orig-
inal tumors.
Taken together, our data confirm recent observations
indicating the potential of CD133+ cells to drive tumor
growth (O’Brien et al., 2007; Ricci-Vitiani et al., 2007).
SpheroidCultures of ColonCancer Stem-likeCells
In an attempt to keep the colon cancer cells in culture for
additional characterization, freshly purified cells were
seeded under standard adherent conditions. These cul-
tures were all characterized by clusters of polygonals cells
(Figure 2A, left panels) that grew up to about 2 weeks. The
adherent cells were positive for CDX2, cytokeratin-AE
(CKAE), CK20, and b-catenin, whereas CK7 was unde-
tectable, which is a typical pattern for colorectal cells (Fig-
ure 2A, left panels). Intriguingly, none of the cells in such
culture conditions was positive for CD133 (Figure 2D
and data not shown). In contrast, when colon carcinoma
samples from the same patients were dissociated into sin-
gle cells and cultured in a serum-free medium containing
EGF and FGF-2, a sphere-like culture was obtained with
a frequency of 10 out of 21 tumors (45%) (Table 1; Fig-
ure 2B, left panel). The sphere-like aggregates could be
expanded for several months in this medium in line with
previous reports on neural and mammary stem cells
(Dontu et al., 2003; Singh et al., 2004). Spheroid growth
appeared to be more effective when using MSI tumors,
but is not exclusive for such tumors (Table 1).
These spheroid cultures were all characterized by cells
with round shape that were negative for CDX2, CK20, and
CK7, but positive for CD133 (Figures 2A and 2B). As as-
sessed by FACS analysis, about 90% of the spheroid cells
were positive for CD133 protein (Figure 2C). Further im-
munoblot analyses assessed on control, cancer adherent
cells and cancer spheres confirmed the expression of
CD133 on cancer spheroid cells (Figure 2D), indicating
that spheroid cultures contain cells that have the same
cell surface marker as the CSC observed within the origi-
nal tumor. In agreement, these spheroid cultures can be
directly derived from the CD133+ colon cancer cells as pu-
rified CD133+ cells from 5 out of 21 different tumor spec-
imens formed spheroids and grew exponentially as undif-
ferentiated cells. This latter capacity seems to correlate
with MSI-high tumors, although it is also observed with
one MSS colon carcinoma (Table 1).
Spheroid cultures that were supplemented with fetal
bovine serum (FBS) for up to 21 days initially displayed ad-
herence to the culture dishes and subsequently differenti-
ated into large, polygonal colon cells starting fromweek 1,
a phenotype similar to that of the adherent primary cul-
tures (Figure S2A).c.
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Role of IL-4 on Colon Cancer Stem CellsFigure 1. Colorectal Cancer CD133+ CSC
(A) Alcian blue, H&E stainings, and immunohistochemical analysis of CK7, CK20, Ki67, CDX2, or CD133, revealed by AEC (red staining), on paraffin-
embedded sections of colorectal cancer. Nuclei are revealed by hematoxylin staining (blue). One representative of nine different tumors is shown.
(B) Confocalmicroscopyanalysis of CD133 on freshly purifiedbulk cells fromcolon cancer specimen. Nuclei were counterstained byHoechst (blue color).
(C) Flow cytometry analysis for CD133 performed on CD133-depleted colon cancer cells using magnetic beads. Data are representative of 21 tumors
analyzed.
(D) In vivo growth of colon carcinoma tumor cells. Colon carcinoma specimens were digested and colon cancer cells were either injected directly into
the right flank of mice (closed triangles and circles) or first magnetically separated for CD133 positive (open squares and diamonds) and depleted of
CD133 cells (gray square) and then injected. Data are mean tumor size ± SD of 15 tumors per group derived from three independent experiments from
different patients. Histology panels represent Alcian blue and H&E staining of xenografted tumors and confirm a colorectal cancer phenotype.More importantly, when colon cancer spheroids were
cultured in the presence of FBS in matrigel, which repre-
sents a reconstituted 3D culture system, colonies that
were generated were organized in a complex structureCereminiscent of a colonic crypt (Figure 2E; Figure S2B, up-
per panels), whereas primary cancer cells from the adher-
ent cultures failed to form these structures (Figure S2B,
lower panels). These crypt-like structures were positivell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc. 391
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Role of IL-4 on Colon Cancer Stem CellsTable 1. Case Description and Tumor Features
Patient Age/Sex Site Dukes
Spheres
Formation CD133 (%) MSI
CD133-Derived
Spheres
Anti-IL-4
Sensitization
P1 65/M recto-sigmoid B yes 1.8 MSI-L no yes
P2 70/M sigma C no 0.3 MSS no nt
P3 55/F left A no 1.2 MSS no yes
P4 68/F sigma B no 1 MSS no nt
P5 66/F recto-sigmoid C yes 1.4 MSI-L no yes
P6 58/M sigma A no 0.8 MSS no nt
P7 65/F sigma D yes 1.3 MSI-H yes yes
P8 57/F left D yes 1.5 MSI-H yes yes
P9 73/F right B no 0.3 MSS no yes
P10 63/M recto-sigmoid B yes 1.9 MSI-H no yes
P11 76/M right B no 3 MSI-L no yes
P12 70/F sigma A no 1 MSS no yes
P13 68/M recto-sigmoid D yes 0.9 MSI-L no no
P14 57/M recto-sigmoid C yes 1.3 MSI-H yes yes
P15 76/F sigma C no 1 MSS no yes
P16 56/F left B no 2.1 MSI-L no yes
P17 75/F left C no 1.8 MSS no no
P18 74/F sigma D no 1.2 MSS no yes
P19 56/F sigma D yes 1.5 MSI-L no yes
P20 68/M recto-sigmoid D yes 1.7 MSI-H yes yes
P21 56/F left D yes 2.4 MSS yes yes
Flow cytometry analysis for CD133 was performed on freshly purified cells from human colon tumors.for alcian blue, CK20, and b-catenin, while CD133 expres-
sion was gradually lost (Figure 2E). We therefore conclude
that colon cancer spheroids represent a subpopulation of
cells that contain stem-like features and have the capacity
to differentiate in vitro into luminal structures.
Colon Spheres Can Generate Tumors upon
Xenotransplantation
Subcutaneous injection of low numbers of spheres con-
firmed that the spheroid cells retain the capacity to initiate
tumor growth in nude mice (Figure 2F; Figure S2C; Table
2). As little as 500 spheroid cells were sufficient to obtain
tumor growth (Figure S2C), while 2 3 106 adherent cells
were ineffective (Figure 2F). Histological examination
of xenografts derived from spheroid cultures showed
that these tumors closely resemble the original human
tumor mainly containing differentiated cells and a small
fraction of stem-like cells expressing CD133 marker
(Figure S2D). Importantly, spheroid cultures can be reder-
ived from the xenotransplantated tumors (Figure S2E),
and these retain the stem-like features as they will form tu-
mors that have the original morphology upon reinjection
(Figure S2F). These data therefore indicate that the
CD133+ cells within colon carcinoma can be propagated392 Cell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inin spheroid cultures, represent cancer stem-like cells
that contain tumorigenic capacity, can be reisolated and
transplanted from xenografts, and are able to differentiate
in vitro and in vivo.
CD133+ Cells Are Resistant to Cell Death Due
to IL-4 Production
Since cancer stem cells are thought to be particularly re-
sistant to drug treatments, we analyzed the cell viability
of primary colon cancer cells following exposure to oxali-
platin and/or 5-fluorouracil (5-FU) at clinically relevant
doses or after exposure to the death ligand TRAIL.
Cancer cells or purified CD133 cells from the same hu-
man colon cancer specimens showed a high sensitivity in
vitro to both drugs tested in a dose-dependent fashion
(Figure 3A). The observed sensitivity of the CD133 cells
was not due to death of nontumor cells within this subpop-
ulation as a clear reduction in the number of P53 mutant
cancer cells was detected (Figure S1B). In contrast,
CD133+ cells were largely inert to chemotherapeutic
drugs-induced apoptosis even at the highest dose con-
centrations used (Watanabe et al., 2006). The ED80 values
indicate an approximate 60- and 15-fold difference for
5-FU and oxaliplatin, respectively (Figure 3A).c.
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IL-4 strongly modulates death receptor- and chemother-
apy-induced apoptosis (Stassi et al., 2003; Todaro et al.,
2006). Receptors for IL-4 are expressed on hematopoietic
cells and a range of nonhematopoietic cells including ep-
ithelial, endothelial, muscle, fibroblast, and liver cells. On
nonhematopoietic cells, the receptor complex for IL-4
(type II) is predominantly composed of the IL-4Ra and
IL-13Ra1 chains which heterodimerize upon either IL-4
or low-affinity IL-13 binding (Mentink-Kane et al., 2004).
Another glycoprotein chain implicated in the IL-4R sys-
tem, but with higher affinity for IL-13, is the IL-13Ra2 chain
described to act as strong inhibitor of the IL-13 signaling
by functioning as a decoy receptor (Rahaman et al.,
2002). Intriguingly, colon cancer samples clearly dis-
played high levels of IL-4 expression (Figures 3C–3F; Ta-
ble S2), which was absent in normal colon (Figure 3C). In
addition, IL-4-receptor (IL-4Ra) expression was also de-
tected in colon cancer specimens (Figure 3C). IL-4 and
IL-4Ra were also expressed on cells of spheroid cultures
and on freshly purified CD133+ cells (Figures 3C–3F). In
contrast, the IL-4-related cytokine, IL-13, was undetect-
able on normal and colon cancer epithelial cells, neither
on CD133+ nor in cancer spheroid cells (Figures 3G and
3H; Figure S1C; Table S2), while it was expressed on
smooth muscle and infiltrating gut lamina propria cells of
the normal mucosa (data not shown) (Morimoto et al.,
2006). IL-13Ra2, the decoy for IL-13, was clearly present
in colon epithelial cells, but higher in normal than in colon
cancer cells (Figures 3G and 3H). Combined, these data
suggest that colon cancer cells may display autocrine
IL-4 signaling.
To investigate whether IL-4 constitutes a survival factor
for CD133+ cells, we pretreated freshly isolated cells with
IL-4-neutralizing antibody, and then drug resistance of
CD133+ cells was evaluated. When anti-IL-4 antibody
was followed by oxaliplatin, 5-FU or TRAIL treatment re-
sulted in a significantly enhanced overall cell death rate
(Figure 3B). Best results were obtained when anti-IL-4 was
combined with either oxaliplatin plus 5-FU (p < 0.001) or
oxaliplatin alone (p < 0.001) with no significant difference
between both treatments (Figure 3B). Similarly, anti-IL-4-
induced sensitization to drugs was also observed in the
long-term spheroid cultures (Figures 4A and 4B), and
even anti-IL-4 antibody alone showed a small but consis-
tent decrease in the viable cell number (Figure 4A), sug-
gesting that IL-4 is required for the survival ofCD133+cells.
Mechanistically, we found that anti-IL-4 treatment resulted
in a decreased expression of the antiapoptotic proteins
cFLIP, Bcl-xL, and PED by about 2-fold (Figure 4C), which
may point to an IL-4-induced antiapoptotic program.
These findings indicate that IL-4 protects CD133+ cells
and could thus dictate therapy refractoriness, possibly
through the upregulation of antiapoptotic proteins.
IL-4 Inhibition Enhances Tumor Response
to Oxaliplatin and 5-FU
To test this hypothesis in vivo, we analyzed whether IL-4
blockade enhances chemotherapy efficacy. Since IL-4Celland IL-13 share a common receptor subunit (IL-4Ra), an
efficient way to block cytokine-induced proliferation in
xenotransplants would be to disrupt ligands/receptor in-
teraction. We used a high affinity antagonist of IL-4Ra
characterized by amino acid replacements in two different
positions of the IL-4 molecule (IL-4DM) as strategy to in-
hibit both IL-4 and IL-13 responses (Grunewald et al.,
1998).
Colon cancer spheroids were allowed to grow into the
flank of nude mice until they reached a size of 0.2 cm3.
Tumors formed had the morphological characteristics of
adenocarcinomas and mainly contained CD133 cells,
whereas only a minority of CD133+ was present. Mice
were then treated intraperitoneally (i.p.) twice a week for
3 weeks with IL-4DM or with PBS starting 24 hr before
drug delivery (Figure 5A). In all treated mice, the tumor
response to chemotherapeutic drugs was enhanced by
IL-4DM. Specifically, IL-4DM cotreatment with oxaliplatin
or oxaliplatin plus 5-FU resulted in a marked synergistic
effect on tumor control, whereas a less pronounced effect
was observed with 5-FU and IL-4DM alone (Figure 5A;
Figure S1D).
As the colon cancers examined were not producing IL-
13, we set out to confirm the role of IL-4 directly with the
use of intratumoral injection of neutralizing antibody
against IL-4 (twice a week for 3 weeks). PBS and control
antibody treatment alone did not prevent tumor out-
growth, and anti-IL-4 only had a marginal effect (Fig-
ure 5B). As observed before, intraperitoneal treatment
with oxaliplatin alone delayed tumor growth by about 4
weeks, but when treatment was interrupted, tumor growth
was as rapid as in the sham-treatedmice, as shown by the
steepness of the growth curves (Figures 5A and 5B). By
contrast, cotreatment with anti-IL-4 strongly enhanced
tumor response to chemotherapeutics, similar to the
IL-4DM effect (Figure 5B).
This data suggests that although standard chemothera-
peutic drugs delay tumor outgrowth during the treatment,
when they are combined with IL-4DM or with IL-4 neutral-
izing antibody, the efficacy of chemotherapy is signifi-
cantly enhanced and also more sustained after treatment
interruption (Figures 5A and 5B).
Anti-IL-4 Sensitizes Cancer Stem-like Cells
Themechanism of in vivo cell death sensitization of cancer
cells to drugs-induced apoptosis was evaluated using im-
munohistochemical analysis of anti-IL-4 treated tumors.
TUNEL staining, which reveals apoptotic cells, several
days after the last oxaliplatin treatment, confirmed that
anti-IL-4 plus oxaliplatin resulted in a significant higher
number of apoptotic events compared to oxaliplatin treat-
ment alone (Figure 5C). TUNEL costaining with CD133 to
identify apoptosis in the stem cell compartment is feasible
and showed TUNEL positivity in CD133+ cells in vivo only
when tumors were cotreated with oxaliplatin and anti-IL-4
and not when they were treated with oxaliplatin and con-
trol antibody (Figure 5D). This suggests that CD133+ cells
are also in vivo more resistant than other cancer cells to
drug treatment. In accordance, treatment of xenograftsStem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc. 393
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Role of IL-4 on Colon Cancer Stem CellsFigure 2. Colorectal Cancer Sphere Formation
(A) Phase contrast microscopy and immunofluorescence analysis of CDX2, CKAE, CK20, and CK7 (red color) on primary adherent colorectal cancer
cells (left panels) and mechanically dissociated cancer spheroid cells (right panels). Nuclei were counterstained by Hoechst (blue staining). One rep-
resentative experiment of five different tumors is shown.
(B) Phase contrast microscopy of a colorectal cancer sphere (left panel). Confocal microscopy analysis of CD133 on spheroids (middle panel) and
mechanically dissociated cancer spheroid cells (right panel). Nuclei were counterstained by Hoechst (blue staining). One representative of four dif-
ferent spheroid cultures is shown.
(C) Flow cytometry analysis of CD133 onmechanically dissociated colon cancer spheroid cells. Black histogram represents isotype control. One rep-
resentative of six independent tumors is shown.
(D) Immunoblot analysis of CD133: (1) control epithelial colon cells (cultured for 5 days), (2) primary adherent colon cancer cells, and (3) colon cancer
spheres. Human cord blood CD34+ cells (4) were used as positive control for CD133. Loading control was assessed by b-actin staining. One repre-
sentative of four independent tumors is shown.394 Cell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc.
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Role of IL-4 on Colon Cancer Stem CellsTable 2. Tumorigenicity of CD133+ and Spheroid-Initiating Colon Cancer Cell
Cancer Source Patients
Cell Number
Injected
Xenograft
Formation
Engraftment-Derived
Spheres
Bulk P1-5-7-8-10-13-14-15-17-19-20-21 5 3 105 yes yes
2 3 106 yes yes
Spheres P1-5-7-8-10-13-14-19-20-21 25 yes yes
50 yes yes
CD133+ P1-5-7-8-10-13-15*-19-21 2.5 3 103 yes yes
5 3 103 yes yes
CD133 P1-5-7-8-10-13-19-21 2 3 106 no /
Adherent cells P1-5-7-8-10-13-14-15-17-19-20-21 2 3 106 no /
* This experiment was done using 3.5 3 103 and 7 3 103 CD133+ cells.with oxaliplatin, which resulted in a clear reduction in tu-
mor size (Figures 5A and 5B), led to a significant increase
in the percentage of CD133+ cells (Figure 5E). This means
that the CD133+ cells have a survival advantage when tu-
mors are treated with oxaliplatin and therefore show a rel-
ative increase. On the contrary, cotreatment with anti-IL-4
ablated this selective advantage (Figure 5E). The percent-
age of CD133+ cells in tumor treated with oxaliplatin plus
anti-IL-4 is therefore not significantly different from un-
treated tumors, but the absolute number of CD133+ is
largely reduced (Figure 5E) as the tumor size is reduced
5-fold. We can therefore conclude that IL-4 protects
CD133+ stem-like cancer cells from oxaliplatin treatment
in vivo and thereby precludes optimal tumor control by
chemotherapy.
DISCUSSION
Cancers are heterogeneous populations of cells at multi-
ple differentiation stages that could be the result of ac-
quired mutations and epigenetic differences. Alterna-
tively, differential expression of differentiation markers
could be due to aberrant differentiation orchestrated by
a stem cell population (Phillips et al., 2006). Although
both hypotheses are difficult to proof, our current data
show that colon cancer lesions consist of a large fraction
of differentiated cancer cells and a small population of
cells that express CD133 stem cell marker. From 10 of
the 21 tumors studied, spheroid cultures could be derived,
and this appears more effective when studying MSI and
high-grade tumors. Although this is not a 100% correla-
tion, it suggests that MSI colon carcinomas may contain
specific mutations that facilitate their in vitro growth. In
contrast to the sphere cultures, the adherent cell popula-
tions established from the same tumor were not tumori-
genic in mice, while they display epithelial features andCellreflect the histological variants from which they were
initially derived. Similar observations were also made for
colon (Ricci-Vitiani et al., 2007) and other solid tumors,
such as brain, melanoma, ovarian, prostate, and breast
carcinoma (Bapat et al., 2005; Collins et al., 2005; Dontu
et al., 2004; Fang et al., 2005; Singh et al., 2004).
In analogy with stem cells, CSC are suggested to resist
death-inducing signals as they are slow cycling and ex-
press high levels of drug transporters (Dean et al., 2005).
CSC were also suggested to express high levels of antia-
poptotic proteins and thus resist apoptotic stimuli (Eramo
et al., 2006). Our spheroid cultures confirm these ideas
and show that stem-like tumor cells effectively resist oxa-
liplatin, 5-FU, and TRAIL-induced death cell. Chemother-
apy resistance may in part be due to the slow cycling of
CSC, but TRAIL sensitivity is not dependent on the cell cy-
cle. We therefore believe that expression of antiapoptotic
proteins dictate this resistance. In agreement, sensitiza-
tion of spheroid cells with anti-IL-4 downregulates expres-
sion of three tested antiapoptotic proteins: cFLIP, PED,
and Bcl-xL. Considerable data suggest that some interleu-
kins promote cancer cell survival and expansion by stim-
ulating expression of antiapoptotic genes. For example,
IL-3 increases Bcl-xL levels in myeloid and pro-B cell (Kie-
slinger et al., 2000). Similarly, IL-10 upregulates Bcl-2 ex-
pression in germinal center B cells, while IL-4 increases
survival of malignant B cells (Dancescu et al., 1992).
Others and we recently demonstrated that carcinoma
cells produce IL-4 and IL-10 and that this alters sensitivity
to death receptor- and cytotoxic drug-induced cell death.
Neutralization of both IL-4 and IL-10 significantly in-
creased the effectiveness of death receptors and antineo-
plastic drugs on primary cancer cells (Stassi et al., 2003;
Todaro et al., 2006). We now extend these observations
to colon CSC both in vitro and in vivo. Our data indicate
that IL-4-depended protection is essential for cell death(E) Alcian blue, H&E stainings, and immunohistochemical analysis of CK7, CK20, b-catenin, and CD133 performed on paraffin-embedded sections of
spheroids cultured in matrigel for 20 days. One representative of four independent spheroid cultures is shown.
(F) Size of subcutaneous tumor growth following injection of colon carcinoma cells from adherent culture (diamonds) and sphere cultures (filled and
unfilled triangles) derived from the same colon cancer specimen. Data are mean tumor size ± SD of four tumors per group derived from two separate
patients.Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc. 395
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Role of IL-4 on Colon Cancer Stem CellsFigure 3. Colon CSC Express and Are Protected by IL-4/IL-4R
(A) Effect of 24 hr exposure of bulk, CD133 and CD133+ cells to different concentrations of oxaliplatin or 5-FU.
(B) Percentage of cell viability in freshly obtained colon cancer specimens was analyzed on bulk cells (white bars), on CD133+-sorted (black bars), or
CD133+-sorted (gray bars) cells. Cells were pretreated or not with 10 mg/ml of anti-IL-4 for 24 hr and then cultured with oxaliplatin (100 mM), 5-FU396 Cell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc.
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Role of IL-4 on Colon Cancer Stem Cellsresistance of colon CSC. Importantly, we observed that
standard drug treatment is indeed effective in vivo in de-
laying tumor outgrowth but after cessation of treatment
tumor growth is accelerated. This is consistent with the
hypothesis that CSC when left unharmed will rapidly
regenerate the original tumor. Our findings on IL-4 proof
to be a general phenomenon in colon cancer as it was
observed in all samples tested (16 out 18 tested) and not
related to stage, location of the tumor, or MSI. These find-
ings may thus provide the means to counteract tumor
regeneration by selectively killing CSC.
The IL-4 dependent resistance of tumor cells is likely to
be a tumor autocrine event, at least in our experimental
conditions. In vitro, IL-4-dependent survival of colon can-
cer cells or CD133+ cells was clearly demonstrated to oc-
cur as an autocrine event. In vivo, a possible paracrine ef-
fect of IL-4 can be excluded as well for several reasons.
First of all, tumor-derived IL-4 was previously suggested
to affect the T cell response, but all our in vivo experiments
were performed on T cell-deficient mice, excluding an ef-
fect of anti-IL-4 on T cell-dependent immunity. Second,
IL-4 has long been recognized for its strict species-spe-
cific character (Morrison and Leder, 1992), that is, tumor-
derived human IL-4 is incapable of acting on the mouse
IL-4Ra and mouse IL-4 does not influence human (tumor)
IL-4Ra. The IL-4 related-cytokine IL-13 is not species spe-
cific and shares with IL-4 not only the common subunit
IL-4Ra, but also some common signaling pathways. Thus,
we used a specific inhibitor for the IL-4Ra subunit to effec-
tively block either cytokine signaling. In addition we also
tested an IL-4 neutralizing antibody specific for human
IL-4. Both strategies enhanced the tumor response to
chemotherapeutic drugs in the same extent, suggesting
that the tumor control observed in our murine model
was primarily due to impaired IL-4- rather than IL-13-me-
diated signaling. We can conclude that the in vivo effect of
tumor-derived IL-4 could solely be propagated via tumor
receptors, similar to what we observed in the isolated
in vitro assays, and it is likely that IL-4 produced by colon
cancer cells installs an antiapoptotic program in cancer
stem-like cells that protects them from chemotherapy.CAlthough in our study the immune-system was ruled out
to better understand themechanism underlying survival of
tumor stem-like cells, this is not the environment for real
epithelial tumors; in fact, many studies in humans reported
infiltration of various tumor types with immunoregulatory T
cells (Gabrilovich, 2004). In general, inflammatory reac-
tions mediated by Th2 (IL-4 and IL-13) cytokines are
known to be the primary cause of several pathologies
when they become chronic (Mentink-Kane et al., 2004).
In primary prostate, breast, and bladder cancer continu-
ous in vivo production of IL-4 was observed, and cancer
cells undergo apoptosis only in the absence of this cyto-
kine (Conticello et al., 2004). There is also recent evidence
that CD4+ T cells infiltrating breast cancer tumors secrete
high levels of Th2 cytokines that actually promote cancer
cell proliferation, which is counteracted with IL-13 antag-
onist (Aspord et al., 2007).
Although these studies demonstrate the presence of IL-
4 or IL-13 inmalignancies, themechanism that determines
which of these cytokines dominate the biological re-
sponses and how the components of IL-4/IL-13 receptor
complex are regulated are poorly understood. In colon
carcinoma there appears to be a primary role for IL-4, as
IL-13 is not expressed in the tumor cells, while the IL-13
decoy receptor is. Moreover, anti-IL-4 is as effective as
the IL-4DM in blocking the resistance.
The contribution of IL-4 to chemotherapy resistance
described in this work contribute to a better understand-
ing of the biological consequences of IL-4 upregulation
and the factors that may determine tumor escape from
current therapies. Combined, our observations may proof
to be of critical importance in future antitumor therapies,
as it has been hypothesized that a surviving small popu-
lation of cancer stem cells could be responsible for
tumor reappearance after an apparent complete regres-
sion and thus could contribute to minimal residual dis-
ease (MRD). The data presented here provide a rational
to use anti-IL-4 as a novel approach in antitumor thera-
pies and suggest further investigations into the under-
lying mechanism of tumor-specific IL-4 expression and
resistance.(50 mg/ml), oxaliplatin plus 5-FU, or TRAIL (200 ng/ml) for an additional 24 hr. Data are mean ± SD of six independent experiments, each performed
with cells from different donors.
(C) Immunostaining analysis of IL-4 and IL-4Ra on paraffin-embedded normal and colorectal carcinoma sections and on colon cancer spheres (red
staining). Nuclei were counterstained by hematoxylin or Hoechst (blue color). One representative of 21 tumors for paraffin sections and seven inde-
pendent experiments for spheres is shown.
(D) Immunoblot analysis of IL-4 and IL-4Ra in (1) control epithelial colon cells, (2) primary adherent colon cancer cells or (3) colon cancer spheres and
their relative band density. PMA/Ionomicyn treated Jurkat cells (4) were used as positive control. Loading control was performed by b-actin staining.
Western blot is one representative out of three performed. Graph represents the mean ± SD of these three independent experiments, each using cells
from different patients.
(E) Flow cytometry analysis of IL-4 and IL-4Ra on freshly isolated magnetically sorted CD133+ cells, PMA/Ionomicyn-treated Jurkat cells, control ep-
ithelial colon cells (cultured for 5 days), and K562 cells (control = unfilled, stained = filled histogram). One representative of four independent exper-
iments is shown.
(F) mRNA expression of IL-4 in control epithelial colon cells, adherent colon cancer cells, colon cancer spheroid, or freshly isolated CD133+ cells.
PMA/Ionomicyn-treated Jurkat cells were used as positive controls. One representative patient of three is shown.
(G) Immunostaining analysis of IL-13 and IL-13Ra2 as in (C). Representative for 20 tumors (paraffin sections) and four spheroid cultures.
(H) Immunoblot analysis of IL-13 and IL-13Ra2 in (1) control epithelial colon cells, (2) primary adherent colon cancer cells, (3) colon cancer spheres, (4)
hIL-13 or (5) human glioblastoma cell line TB10 as positive control. Loading control was performed by b-actin staining. Immunoblot is one represen-
tative out of three performed.ell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc. 397
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Role of IL-4 on Colon Cancer Stem CellsFigure 4. IL-4 Protects Colon Cancer Spheres from Cell Death
(A) Cell viability percentage of colon cancer spheres pretreated for 24 hr or not with 10 mg/ml of anti-IL-4 and then cultured with oxaliplatin, 5-FU,
oxaliplatin plus 5-FU or TRAIL for additional 24 hr. Data represent mean ± SD of four independent experiments each performed with cells from dif-
ferent donors.
(B) Immunofluorescence analysis of orange acridine/ethidium bromide stained colon cancer spheres treated as in (A). One representative of six in-
dependent experiments is shown.
(C) Immunoblot analysis of cFLIP, PED, and Bcl-xL in colon cancer spheres (1) cultured in the presence of neutralizing antibody against IL-4 for 48 hr
(2) and its relative band density of four independent experiments, each using spheres fromdifferent patients. Loading control was assessed by b-actin
staining.398 Cell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc.
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Role of IL-4 on Colon Cancer Stem CellsEXPERIMENTAL PROCEDURES
Tissue Collection, Isolation, and Culture of Cancer Cells
Human colon tissue fragments were obtained in accordance with the
ethical standards of the institutional committee on human experimen-
tation from 21 patients (age range 55–70 years) undergoing a colon re-
section for colon adenocarcinoma. Histological diagnosis was based
on microscopic features of carcinoma cells determining the histologi-
cal type and grade. Cancer tissues were intensively washed four times
in PBS solution containing antibiotics and incubated overnight in
DMEM/F12 (GIBCO) containing penicillin (500 U/ml), streptomycin
(500 mg/ml), and amphotericin B (1.25 mg/ml) (GIBCO). Enzymatic di-
gestion was performed using collagenase (1.5mg/ml) (GIBCO) and hy-
aluronidase (20 mg/ml) (Sigma Chemical) in PBS for 1 hr. Then, the di-
gests were used for (1) direct engraftment, (2) depletion or purification
of CD133+ cells (see below), (3) culturing in DMEM supplemented with
10% fetal bovine serum (FBS), L-glutamine and 1x antibiotic-antimy-
cotic (GIBCO) onto collagen (Calbiochem) coated flasks to obtain pri-
mary colon cells, and (4) culturing in stem cell medium DMEM/F12
(GIBCO) supplemented with 6 mg/ml Glucose, 1 mg/ml NaHCO3,
5 mM HEPES, 2 mM L-Glutamine, 4 mg/ml Heparin, 4 mg/ml BSA,
10 ng/ml bFGF, 20 ng/ml EGF, 100mg/ml apotrasferrin, 25 mg/ml insulin,
9.6 mg/ml putrescin, 30 nM sodium selenite anhydrous, and 20 nM pro-
gesterone (Sigma) to obtain spheroids. To enhance epithelial in vitro
cytodifferentiation of stem cell-like cells, spheroids were exposed to
DMEM supplemented with 1% FBS. All cell culture was carried out
at 37C in a 5% CO2 humidified incubator.
Control tissue specimens, obtained from the peritumoral tissues of
the surgically removed specimens, were digested with collagenase P
(0.4 U/ml) and dispase I (1.2 U/ml) for 4 min at 37C. Cells were ob-
tained by mechanical dissociation of crypts and kept in culture up to
5 days (Fonti et al., 1994).
Magnetic Sorting and Flow Cytometry
Magnetic cell separation was performed on tumor cell populations ob-
tained from enzymatic dissociation of colon cancer specimens using
microbeads conjugated with CD133/1 (AC133, mouse IgG1, cell isola-
tion kit, Miltenyi). The magnetic separation step was repeated twice,
applying the eluted cells to a new positive selection column. After mag-
netic sorting, viability was assessed using trypan blue exclusion. Qual-
ity of sorting was controlled by flow cytometry with an antibody against
CD133/2 (293C3-PE, Miltenyi) on both CD133+ and CD133 depleted
cell population. Fractionated and nonfractionated cells from human
specimens and xenografts (see below) were analyzed for CD133 ex-
pression using CD133/2 (293C3-PE, Miltenyi). IL-4 and IL-4Ra expres-
sion were assessed on CD133+ cells using FITC-conjugated anti-IL-4
(B-S4, mouse IgG1, Bender), biotin-conjugated anti-CD124 (hIL4R-
M57, mouse IgG1, BD PharMingen), or isotype-matched control
(mouse IgG1 FITC and mouse IgG1 biotinylated BD PharMingen and
rabbit anti-CD33Chemicon). Streptavidin-FITC was used for detection
of IL-4Ra. Cells were washed and analyzed by flow cytometry. Jurkat
exposed for 4 hr to PMA (10 ng/ml) and ionomicyn (1 mM), control co-
lonocytes cultured for 5 days and K562 cell lines were used as positive
and negative controls respectively.
In Vitro Cell Death Analysis
Freshly isolated colon cancer cells were either cultured as nonfractio-
nated or first magnetically sorted into CD133+ and CD133 cells and
then cultured in DMEM plus 1% FBS. Where indicated, cells were pre-
treated for 24 hr with anti-human IL-4 (10 mg/ml) (R&D Systems). Sim-
ilarly, spheroid cultures from the same tumor specimen were cultured
in the presence or absence of anti-human IL-4 in stem cell medium.
Fresh anti-IL-4 (10 mg/ml) was added after 24 hr and cells were subse-
quently treated for an additional 24 hr with oxaliplatin (100 mM) (Sigma)
or with 5-FU (50 mg/ml) (Sigma) or in combination (oxaliplatin plus
5-FU) or iso-leucine zipper TRAIL (200 ng/ml; iz-TRAIL kindly provided
by H. Walczak), after which cell death was determined. Viability of
freshly isolated CD133+, CD133, and complete pool cells was evalu-Celated using CellTiter Aqueous Assay Kit (Promega). Percentage of cell
death on colon cancer spheres was evaluated by DNA staining fol-
lowed by flow cytometry analysis. Moreover, cell death on colon can-
cer spheres was evaluated by confocal analysis of orange acridine/
ethidium bromide stained cells.
Histochemistry, Immunohistochemistry/Fluorescence,
and TUNEL Staining
Histochemical analysis was performed on 5-mm-thick paraffin-embed-
ded sections of colon specimens or in 3D cell culture. H&E- and Alcian
blue-stained sections were dehydrated and mounted in synthetic
resin. Slides were heated for antigen retrieval in 10 mM sodium citrate
(pH 6.0). After rinsing in dH2O, inhibition of endogenous peroxidase
was performed with 3% H2O2 (5 min). After two washes in TBS, slides
were incubated with 10% human serum for 20 min to block unspecific
staining. Following elimination of excess serum, sections were subse-
quently exposed to specific antibodies against cytokeratin 7 (OVTL
mouse IgG1K, BioGenex), cytokeratin 20 (IT-Ks20.8 mouse IgG2a, Bio-
Genex), Ki67 (MIB-1 mouse IgG1, Dako), CDX2 (CDX2-88 mouse IgG1,
Biocare), CD133/2 (Miltenyi), b-catenin (17C2 mouse IgG2a Novocas-
tra), IL-4Ra (C-20 rabbit IgG, Santa Cruz), IL-4 (B-S4 mouse IgG1,
Bender MedSystems), IL-13 (B-P6 mouse IgG1, Bender), IL-13 Ra2
(AF146 goat IgG, R&D Systems), or isotype-matched controls at ap-
propriate dilutions overnight at 4C. Then sections were washed in
TBS and incubated with biotinylated anti-mouse or anti-rabbit immu-
noglobulins for 30 min at room temperature and treated with streptavi-
din-peroxidase (LSAB2 Kit, Dako). Staining was revealed using AEC
substrate and counter-stained with hematoxylin.
Immunofluorescence was performed on spheroids, onmechanically
dissociated spheroid cells, or on primary adherent cultures of colon
cancer cells for cytokeratin 20 (BioGenex), CD133/2 (Miltenyi),
IL-4Ra (Santa Cruz), IL-4 (Caltag), IL-13 (Bender), IL-13 Ra2 (R&D
Systems) cytokeratin 7 (BioGenex), cytokeratin A/E (AE1/AE3 mouse
IgG1, Dako), and CDX2 (Biocare Medical) stained sections were
treated with Rhodamine Red-conjugated anti-mouse or anti-rabbit an-
tibodies (Molecular Probes, Inc., Eugene, OR). Counterstaining was
performed using Hoechst 33342. Confocal analysis was used to ac-
quire fluorescence staining.
TdT-mediated dUTP nick end labeling (TUNEL)-reaction was per-
formed on paraffin-embedded CD133-labeled engrafted tumor sec-
tions (10 mm). Specimens were postfixed with paraformaldehyde and
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. Apopto-
sis was determined by In Situ Cell Death Detection, AP Kit (Boehringer
Mannheim). DNA strand breaks were detected by 5-bromo-4-chloro-
3-indolyl-phosphate (BCIP, dark blue color, Dako) substrate. Positive
control was performed by pretreating specimens with DNase I, while
the negative control was represented by CD133 positive specimens
subjected to the same staining for TUNEL without TdT.
Protein Isolation and Western Blotting
Spheroids and cell pellets were resuspended in ice-cold NP-40 lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1% NP-
40) containing protease inhibitors. Lysates (30 mg/lane) were applied
to SDS-PAGE. Immunoblotting of Abs specific for CD133/2 (AC141
mouse IgG1, Miltenyi), IL-4 (MAB304, mouse IgG1, R&D Systems),
IL-4Ra (MAB230, mouse IgG2a, R&D Systems), IL-13 (Bender), IL-13
Ra2 (R&D Systems), cFLIP (NF6 mouse IgG1, Alexis), PED/PEA-15
(rabbit IgG kindly provided by G. Condorelli) and Bcl-xL (H-5, mouse
IgG1; Santa Cruz), or actin (Ab-1, mouse IgM, Calbiochem) were de-
tected using HRP-conjugated anti-mouse or anti-rabbit Abs (Amer-
sham) and visualized by chemiluminescence detection system (West
Dura Substrate, Pierce).
Real-Time PCR
Total RNA was extracted and reverse transcribed. TaqMan PCR reac-
tions were performed with ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) using 13 probes and primer sets
Hs00174122_m1 (IL-4), Hs00174379_m1 (IL-13) or Hu GAPDHl Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc. 399
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Role of IL-4 on Colon Cancer Stem CellsFigure 5. Neutralization of IL-4 Sensitizes Colon Cancer Cells to Cell Death In Vivo
(A) Size of subcutaneous colon carcinoma tumors derived from spheroid injection of a MSS tumor up to 90 days after i.p. treatment with PBS or
IL-4DM alone or in combination with oxaliplatin, 5-FU or oxaliplatin plus 5-FU. Data aremean ± SD of five tumors per group derived from one spheroid
culture.
(B) Tumor size derived as in (A) after intratumoral injection of anti-IL-4 or control IgG alone or in combination with i.p administration of oxaliplatin or
PBS. Data are mean tumor size ± SD of 12 tumors per group derived from two independent experiments using spheroid cultures from different MSI
patients.
(C) Percentage of apoptotic events measured on sections of subcutaneous tumors (4 per group) treated as in (B) and stained for TUNEL. **p < 0.01.
5 3 105 cells per tumor were counted and the percentage of apoptotic cells calculated. Samples were analyzed 6 weeks after treatment started.
(D) CD133 (red color, white arrows) and TUNEL (dark blue color, red arrowheads) double staining of tumors treated as in (B).400 Cell Stem Cell 1, 389–402, October 2007 ª2007 Elsevier Inc.
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Role of IL-4 on Colon Cancer Stem Cells(Applied Biosystems). The reaction conditions were: 95C for 10 min
and 50 cycles at 95C for 15 s and 60C for 1 min. The relative quan-
titation of IL-4 and IL-13 gene expression was calculated using the
comparative Ct method (DDCt). Experimental target quantities were
normalized to the endogenous Hu GAPDH control. Data processing
and statistical analysis were performed using the ABI PRISM SDS,
software version 2.1 (Applied Biosystems). Peripheral blood mononu-
clear cells (PBMC) treated for 4 hr with lipopolysaccharide (LPS)
(10 mg/ml) were used as positive control for IL-13.
Evaluation of Tumorigenicity and Toxicity
Tumorigenicity was determined by s.c. injecting either freshly isolated
enzymatic dissociated tumor cells (Bulk; 0.5 or 2 3 106), freshly iso-
lated CD133-depleted tumor cells (2 3 106), freshly isolated CD133+
cells (2.5 or 5 3 103), adherently growing colon cancer cells (2 3
106), colon cancer spheres (25, 50, and 500), or dissociated spheroids
cells (53 102) into the flank of 5- to 6-week-old female nudemice.Mice
were purchased from Charles River Laboratories (Milan, Italy) and
maintained in accordance to the institutional guidelines of the Univer-
sity of Palermo animal care committee. After 10 days, when well-es-
tablished tumors of about 0.25 cm3 were detected, 12 mice per group
were i.p. treated with a specific inhibitor of IL-4Ra, IL-4DM (3 mg/Kg/
day twice a week, for 3 weeks) which has substitution at positions 121
(Arg/Asp) and 124 (Tyr/Asp) (kindly provided by Apogenix) (Zuraw-
ski et al., 1993) alone or in combination with oxaliplatin (0.25 mg/kg
once a week for 4 weeks) and/or with 5-FU (15 mg/kg/day for 5 days
a week for 2 weeks). Additional treatments with neutralizing Abs
against IL-4 (R&D Systems; 10 mg/cm3 twice a week for 3 weeks)
administered into the tumor alone or in combination with oxaliplatin
(i.p.) were performed in another group of 12 mice. Controls were
carried out using IgG isotype matched control antibody or PBS (un-
treated). Tumor size was measured twice weekly using the formula:
(p/6) 3 larger diameter 3 (smaller diameter)2. Incidence of cell death
and CD133+ cells was determined 6 weeks after spheroid injection us-
ing AC133 and TUNEL staining on aminimum of 10 sections per tumor
and a total of around 5 3 105 tumor cells per sample. Counting was
performed blinded and by two independent observers on four samples
per group derived from two independent spheroid cultures (different
patients).
Statistical Analysis
Percentage of apoptotic events was calculated from the number of
cells stained for TUNEL on paraffin-embedded sections of subcutane-
ous tumors. 5 3 105 cells were counted per tumor (n = 4).
For in vitro cell death quantification, percentage of cell death was
derived from the percentage of viable cells that was calculated by
MTS assay or the Propidium Iodide staining. CD133+ cells percentage
was calculated from the positivity for CD133 observed on paraffin-
embedded engrafted tumor tissues counted by two independent
observers or flow cytometry analysis assessed on engrafted-derived
complete pool cells. Analysis of Variance (one-way or two-way) with
Bonferroni post-test was used to analyze the statistical significance
of the experimental results. Results were considered significant
when p values were less than 0.05.
Intensity of band signals in exposed filmwas determined by densito-
metric scanning and analyzed using NIH IMAGE software version 1.62
(by Wayne Rasband, National Institutes of Health, Research Services
Branch, NIMH). Results were expressed as protein/b-actin OD ratio
(OD). Data were expressed as mean ± standard deviation of the mean.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, two supplemental figures, and two supplemental tables andCelcan be found with this article online at http://www.cellstemcell.com/
cgi/content/full/1/4/389/DC1/.
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